Icon Plc (ICLR)
NASDAQ:ICLR
Want to see ICLR full AI Analyst Report?
Earnings Data
Report Date
Jul 29, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
2.56Last Year’s EPS
3.26Same Quarter Last Year
Moderate Buy
Based on 13 Analysts Ratings
Earnings Call Summary
Q4 2025
Earnings Call Date:Feb 25, 2026|
% Change Since:
|
Earnings Call Sentiment|Neutral
Mixed: the call highlighted clear commercial momentum (bookings up 19%, improved win rates and book‑to‑bill of 1.36x), strong cash generation and strategic investments, and management provided conservative yet constructive 2026 guidance with expected margin progression. However, the independent investigation, identified material weaknesses in controls, restatements, significant cost‑to‑complete adjustments (> $50M) and notable margin and earnings deterioration (adjusted EBITDA and EPS declines; GAAP EPS down sharply) are material negatives that temper the outlook.Company Guidance
Strong bookings and commercial momentum
Net bookings of $2.9B in Q4, up 19% year‑over‑year; gross bookings of $3.2B; direct‑fee book‑to‑bill of 1.36x. RFP flow increased in the low double digits and biotech win rates improved by ~5 percentage points sequentially. Cancellations fell to $365M in the quarter, meaningfully lower than elevated levels earlier in the year.
Revenue beat and pass‑through strength in Q4
Q4 revenue of $2.1B, +2.5% year‑over‑year and +1.3% sequentially; Q4 revenue was approximately $100M higher than the midpoint expectation due largely to pass‑through revenue coming in >$150M higher than anticipated.
Solid cash generation and shareholder returns
Q4 operating cash flow of $234.2M and Q4 free cash flow of $174.8M; full‑year free cash flow of $862M. Ended Q4 with $647.3M cash and $3.4B debt (net debt ~$2.8B) and leverage of 1.8x net debt / adj. TTM EBITDA. Significant share repurchases of $750M at an average price of $167.
Strategic portfolio moves and capability investments
Completed divestiture of Symphony Health (reduces FY revenue by ~2%) while retaining access to broader data assets via partner; expanded lab services (added >100 new biomarker assays); opened new Phase I clinic in San Antonio (130+ beds) and satellite centers; launched partnership with Advarra and continued investment in AI capabilities (Orbis, CRA and contracting agents) to drive productivity and differentiation.
2026 guidance with expected margin progression
Issued FY2026 guidance of revenue $7.85B–$8.15B and adjusted EPS $10.00–$11.00. Management indicated midpoint implies an approximate 16.5% EBITDA margin for 2026 and expects sequential margin improvement through the year, exiting at a higher run‑rate.
ICLR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ICLR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 29, 2026 | $102.49 | $116.17 | +13.35% |
Feb 25, 2026 | $104.09 | $101.00 | -2.97% |
Oct 22, 2025 | $192.60 | $180.00 | -6.54% |
Jul 23, 2025 | $167.89 | $195.01 | +16.15% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Icon Plc (ICLR) report earnings?
Icon Plc (ICLR) is schdueled to report earning on Jul 29, 2026, After Close (Confirmed).
What is Icon Plc (ICLR) earnings time?
Icon Plc (ICLR) earnings time is at Jul 29, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ICLR EPS forecast?
ICLR EPS forecast for the fiscal quarter 2026 (Q2) is 2.56.